🔗 Share this article

Chancellor Reeves has stated she is preparing "targeted action to address household expense challenges" in next month's financial statement.

During an interview with the BBC, she emphasized that curbing price rises is a joint task of both the administration and the central bank.

The United Kingdom's inflation rate is projected to be the highest among the Group of Seven developed nations this calendar year and next.

Possible Utility Bill Interventions

Sources suggest the administration could take action to bring down energy bills, for example by reducing the current 5% rate of VAT applied on energy.

An additional approach is to reduce some of the regulatory levies presently included in household expenses.

Budgetary Limitations and Analyst Expectations

The administration will receive the latest draft from the official forecaster, the OBR, on Monday, which will reveal how much space there is for such actions.

The expectation from the majority of analysts is that the Chancellor will have to introduce tax increases or spending cuts in order to fulfill her declared fiscal targets.

Earlier on the same day, calculations showed there was a £22 billion gap for the Treasury chief to resolve, which is at the lower end of projections.

"There's a shared job between the Bank of England and the administration to bear down further on some of the causes of inflation," Reeves told the BBC in Washington, at the conferences of the International Monetary Fund and World Bank.

Tax Commitments and Global Concerns

While much of the attention has been on probable tax rises, the chancellor said the most recent figures from the OBR had not changed her commitment to election pledges not to raise rates on income tax, VAT or National Insurance.

She attributed an "unpredictable global environment" with increasing international and trade tensions for the fiscal tax moves, likely to be focused on those "most able to pay."

International Trade Disputes

Referring to worries about the United Kingdom's commercial links with China she said: "Our national security invariably take priority."

Recent announcement by Chinese authorities to tighten trade restrictions on rare earths and other materials that are key for high-technology manufacturing led American leader Donald Trump to suggest an additional 100% tariff on goods from the Asian country, increasing the possibility of an all-out trade war between the two largest economies.

The US Treasury Secretary labeled the Chinese move "economic coercion" and "a international production control attempt."

Inquired about considering the US offer to participate in its battle with China, the Chancellor said she was "extremely troubled" by Chinese measures and called on the Beijing authorities "to avoid restrictions and restrict access."

She said the action was "bad for the international commerce and generates additional obstacles."

"In my view there are areas where we must challenge China, but there are also significant opportunities to export to China's economy, including financial services and other areas of the economy. We've got to maintain that equilibrium appropriate."

The Treasury chief also affirmed she was collaborating with international partners "regarding our own essential resources approach, so that we are less reliant."

Health Service Medicine Pricing and Investment

The Chancellor also admitted that the price the National Health Service spends on drugs could go up as a result of ongoing talks with the US government and its pharmaceutical firms, in return for lower tariffs and funding.

A number of the biggest global pharmaceutical manufacturers have said recently that they are either halting or abandoning investments in the United Kingdom, with several blaming the low prices they are receiving.

Recently, the government science advisor said the price the health service spends on medicines would have to increase to prevent firms and pharmaceutical investment leaving the United Kingdom.

Reeves stated to media: "We have seen as a result of the pricing regime, that clinical trials, innovative medicines have not been provided in the United Kingdom in the extent that they are in other EU nations."

"We want to make sure that people receiving treatment from the NHS are can obtain the finest life-saving treatments in the world. And so we are reviewing all of that, and... looking to secure more funding into the UK."